Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight? (IUGR)
|Fetal Growth Retardation||Drug: Innohep (Tinzaparin) Drug: tinzaparin||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Can Treatment With Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?|
- birth weight [ Time Frame: Birth weight registered at birth ]We compare birth weight in children born of women from the 2 study arms
- maternal morbidity [ Time Frame: Comorbidity registered up to one year after birth ]
|Study Start Date:||July 2011|
|Study Completion Date:||July 2016|
|Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
Active Comparator: Innohep
Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
Drug: Innohep (Tinzaparin)
Dose: 4,500 IU daily in half of the study populationrandomised to treatment
Other Name: InnohepDrug: tinzaparin
Dose 4,500 IE daily
Other Name: Innohep
|No Intervention: no treatment|
1. To examine whether treatment with low molecular weight heparin in pregnant women with Intrauterine Growth Restriction (IUGR)increases the birth weight of the child. Our hypothesis is that an increased birth weight leads to reduced morbidity and mortality among these children.
- To evaluate three new methods to monitor the effect of LMWH.
- To investigate if 2 biochemical markers are positive predictors of IUGR IUGR is defined as a foetus that grows less than expected. IUGR is estimated to occur in up to 5% of all pregnancies, and IUGR is the second most common cause of perinatal morbidity and mortality. Thus, 75% of all stillbirths are caused by IUGR. IUGR is diagnosed by ultrasonography. In IUGR the uteroplacental blood flow is often compromised resulting in foetal growth restriction.
Design: The study is a prospective randomised study where pregnant women with suspected severe IUGR are randomised either to treatment with Innohep® or no treatment. Half of the women receive Innohep® and half of the women do not receive treatment.
Endpoints The primary endpoint is the difference in birth weight in children born of women receiving Innohep® during pregnancy and children born of women who have not received Innohep® during pregnancy
Please refer to this study by its ClinicalTrials.gov identifier: NCT01390051
|Consultant phD professor Anne-Mette Hvas|
|Aarhus, Central Denmark Region, Denmark, 8200|
|Department of Obstetrics|
|Herning, Denmark, 7400|
|Department of Obstetrics|
|Principal Investigator:||Anne-Mette Hvas, PhD, professor||Department of Clinical Biochemistry, Aarhus University Hospital, Denmark|